12:00 AM
 | 
Jan 09, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Diltiazem: Completed Phase III enrollment

Ventrus completed enrollment of 465 patients with anal fissures in a double-blind, placebo-controlled, European Phase III trial evaluating 2% and 4% diltiazem cream for 8...

Read the full 105 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >